Skip to content

Study · Animal study (in vivo) · mouse · 2017

6 results

Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis.

Nairz M, Haschka D, Dichtl S, Sonnweber T, Schroll A, Aßhoff M, Mindur JE, Moser PL, Wolf D, Swirski FK, Theurl I, Cerami A, Brines M, Weiss G

Scientific reports12 Oct 2017Cited by 17 (Europe PMC)

PMID29026145 (opens in a new tab)PMCIDPMC5638901 (opens in a new tab)DOI10.1038/s41598-017-13046-3 (opens in a new tab)PepBankPUB-29026145
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

Two distinct forms of the erythropoietin receptor (EPOR) mediate the cellular responses to erythropoietin (EPO) in different tissues. EPOR homodimers signal to promote the maturation of erythroid progenitor cells. In other cell types, including immune cells, EPOR and the ß-common receptor (CD131) form heteromers (the innate repair receptor; IRR), and exert tissue protective effects. We used dextran sulphate sodium (DSS) to induce colitis in C57BL/6 N mice. Once colitis was established, mice were treated with solvent, EPO or the selective IRR agonist cibinetide. We found that both cibinetide and EPO ameliorated the clinical course of experimental colitis in mice, resulting in improved weight gain and survival. Correspondingly, DSS-exposed mice treated with cibinetide or EPO displayed preserved tissue integrity due to reduced infiltration of myeloid cells and diminished production of pro-inflammatory disease mediators including cytokines, chemokines and nitric oxide synthase-2. Experiments using LPS-activated primary macrophages revealed that the anti-inflammatory effects of cibinetide were dependent on CD131 and JAK2 functionality and were mediated via inhibition of NF-κB subunit p65 activity. Cibinetide activation of the IRR exerts potent anti-inflammatory effects, especially within the myeloid population, reduces disease activity and mortality in mice. Cibinetide thus holds promise as novel disease-modifying therapeutic of inflammatory bowel disease.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with DSS-induced colitis, cibinetide improved weight gain compared with solvent.

    In plain wordsIn mice with colitis, cibinetide improved weight gain compared with solvent.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseWeight gain in DSS colitis
    Study

    mousen: not reported in source

    DSS-induced colitis in C57BL/6 N mice
    Comparator
    Solvent
    Outcome group
    Body weight · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found that both cibinetide and EPO ameliorated the clinical course of experimental colitis in mice, resulting in improved weight gain and survival.
    2 context sentences
    Summary · context
    We used dextran sulphate sodium (DSS) to induce colitis in C57BL/6 N mice.
    Summary · context
    Once colitis was established, mice were treated with solvent, EPO or the selective IRR agonist cibinetide.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with DSS-induced colitis, cibinetide improved survival compared with solvent.

    In plain wordsIn mice with colitis, cibinetide improved survival compared with solvent.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseSurvival in DSS colitis
    Study

    mousen: not reported in source

    DSS-induced colitis in C57BL/6 N mice
    Comparator
    Solvent
    Outcome group
    Mortality · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found that both cibinetide and EPO ameliorated the clinical course of experimental colitis in mice, resulting in improved weight gain and survival.
    2 context sentences
    Summary · context
    We used dextran sulphate sodium (DSS) to induce colitis in C57BL/6 N mice.
    Summary · context
    Once colitis was established, mice were treated with solvent, EPO or the selective IRR agonist cibinetide.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with DSS-induced colitis, cibinetide preserved tissue integrity, with reduced infiltration of myeloid cells.

    In plain wordsIn mice with colitis, cibinetide preserved tissue and reduced immune cell (myeloid) entry into the tissue compared with solvent.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseInfiltration of myeloid cells in colon tissue
    Study

    mousen: not reported in source

    DSS-induced colitis in C57BL/6 N mice
    Comparator
    Solvent
    Outcome group
    Inflammation markers · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Correspondingly, DSS-exposed mice treated with cibinetide or EPO displayed preserved tissue integrity due to reduced infiltration of myeloid cells and diminished production of pro-inflammatory disease mediators including cytokines, chemokines and nitric oxide synthase-2.
    2 context sentences
    Summary · context
    We used dextran sulphate sodium (DSS) to induce colitis in C57BL/6 N mice.
    Summary · context
    Once colitis was established, mice were treated with solvent, EPO or the selective IRR agonist cibinetide.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with DSS-induced colitis, cibinetide diminished production of pro-inflammatory mediators including cytokines, chemokines and nitric oxide synthase-2.

    In plain wordsIn mice with colitis, cibinetide lowered inflammatory signals such as cytokines, chemokines and nitric oxide synthase-2 compared with solvent.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreasePro-inflammatory mediators (cytokines, chemokines, nitric oxide synthase-2)
    Study

    mousen: not reported in source

    DSS-induced colitis in C57BL/6 N mice
    Comparator
    Solvent
    Outcome group
    Inflammation markers · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Correspondingly, DSS-exposed mice treated with cibinetide or EPO displayed preserved tissue integrity due to reduced infiltration of myeloid cells and diminished production of pro-inflammatory disease mediators including cytokines, chemokines and nitric oxide synthase-2.
    2 context sentences
    Summary · context
    We used dextran sulphate sodium (DSS) to induce colitis in C57BL/6 N mice.
    Summary · context
    Once colitis was established, mice were treated with solvent, EPO or the selective IRR agonist cibinetide.
  5. 05LabIn vitro (cells)Mechanism

    In LPS-activated primary macrophages, the anti-inflammatory effects of cibinetide depended on CD131 and JAK2 functionality.

    In plain wordsIn cells, cibinetide's anti-inflammatory effects needed the CD131 receptor part and the JAK2 enzyme to work.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    Not applicableDependence of anti-inflammatory effect on CD131 and JAK2
    Study

    n: not reported in source

    LPS-activated primary macrophages
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    the anti-inflammatory effects of cibinetide were dependent on CD131 and JAK2 functionality and were mediated via inhibition of NF-κB subunit p65 activity.
    1 context sentence
    Summary · context
    Experiments using LPS-activated primary macrophages revealed that the anti-inflammatory effects of cibinetide were dependent on CD131 and JAK2 functionality and were mediated via inhibition of NF-κB subunit p65 activity.
  6. 06LabIn vitro (cells)Mechanism

    In LPS-activated primary macrophages, the anti-inflammatory effects of cibinetide were mediated via inhibition of NF-κB subunit p65 activity.

    In plain wordsIn cells, cibinetide's anti-inflammatory effects worked through lower activity of NF-κB p65, an inflammation switch.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseNF-κB subunit p65 activity
    Study

    n: not reported in source

    LPS-activated primary macrophages
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    mediated via inhibition of NF-κB subunit p65 activity.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.